TG Therapeutics, Inc. (TGTX) Q1 2025 Earnings Call Transcript #Therapeutics #TGTX #Earnings #Call #Transcript
Tag: Therapeutics
CRISPR Therapeutics And Intellia Therapeutics: Balancing Market Uncertainty Against Pipeline Catalysts
CRISPR Therapeutics And Intellia Therapeutics: Balancing Market Uncertainty Against Pipeline Catalysts #CRISPR #Therapeutics #Intellia #Therapeutics #Balancing…
Summit Therapeutics Inc. (SMMT) Q1 2025 Earnings Call Transcript
Summit Therapeutics Inc. (SMMT) Q1 2025 Earnings Call Transcript #Summit #Therapeutics #SMMT #Earnings #Call #Transcript
Novartis to Acquire Regulus Therapeutics in $1.7 Billion Deal, Sending Stock Soaring
As of this writing, Regulus Therapeutics Inc. (RGLS) is one of the top gainers in the…
ZyVersa Therapeutics Announces Published Data Showing Inflammasome ASC Inhibitor IC 100 Decreases Microglial Inflammasome Activation and Alpha-Synuclein That Contribute to Neurodegeneration in Parkins
ZyVersa Therapeutics Announces Published Data Showing Inflammasome ASC Inhibitor IC 100 Decreases Microglial Inflammasome Activation and…
SpringWorks Therapeutics Announces Expected CHMP Opinion in Q2 2025 for Nirogacestat for the Treatment of Adults with Desmoid Tumors in the European Union
SpringWorks Therapeutics Announces Expected CHMP Opinion in Q2 2025 for Nirogacestat for the Treatment of Adults…
Summit Therapeutics: New Ivonescimab Data Raise Concerns (NASDAQ:SMMT)
This article was written by Follow ONeil Trader is a former stockbroker turned full-time independent investor.…
Addex Therapeutics Ltd (ADXN) Q4 2024 Earnings Call Transcript
Addex Therapeutics Ltd (ADXN) Q4 2024 Earnings Call Transcript #Addex #Therapeutics #ADXN #Earnings #Call #Transcript
Viking Therapeutics: Q1 Earnings Overview – Hard To Understand Wall Street's Pessimism
Viking Therapeutics: Q1 Earnings Overview – Hard To Understand Wall Street's Pessimism #Viking #Therapeutics #Earnings #Overview…
Bicycle Therapeutics: Maybe Underwhelming, But I Don't Think They Should Be This Discounted
Bicycle Therapeutics: Maybe Underwhelming, But I Don't Think They Should Be This Discounted #Bicycle #Therapeutics #Underwhelming…
DiaMedica Therapeutics: Stroke Developer With Low Cash Reserve
DiaMedica Therapeutics: Stroke Developer With Low Cash Reserve #DiaMedica #Therapeutics #Stroke #Developer #Cash #Reserve
Viking Therapeutics: Trading The Volatility Of The Weight Loss Drug Market
Viking Therapeutics: Trading The Volatility Of The Weight Loss Drug Market #Viking #Therapeutics #Trading #Volatility #Weight…
Verve Therapeutics: A New Era in Cardiovascular Disease Treatment?
In a major breakthrough, Verve Therapeutics (VERV) has announced positive results from its Heart-2 clinical trial.…
Apogee Therapeutics: Engineering Biologic Dominance
Apogee Therapeutics: Engineering Biologic Dominance #Apogee #Therapeutics #Engineering #Biologic #Dominance
Relay Therapeutics: Trying To Find That Right Price
Relay Therapeutics: Trying To Find That Right Price #Relay #Therapeutics #Find #Price
Abeona Therapeutics: A Buy With Major PDUFA Catalyst On April 29 That Should Send Shares Higher
Abeona Therapeutics: A Buy With Major PDUFA Catalyst On April 29 That Should Send Shares Higher…
Summit Therapeutics: Not Pharmacyclics, Not Yet
Summit Therapeutics: Not Pharmacyclics, Not Yet #Summit #Therapeutics #Pharmacyclics
Adar1 capital management increases stake in Keros Therapeutics with $328k purchase
Adar1 capital management increases stake in Keros Therapeutics with $328k purchase#Adar1 #capital #management #increases #stake #Keros…
Adar1 partners increases stake in Keros Therapeutics with $9.1m purchase
Adar1 partners increases stake in Keros Therapeutics with $9.1m purchase#Adar1 #partners #increases #stake #Keros #Therapeutics #9.1m…
Y-mAbs Therapeutics: A Yawn From The Market Means Opportunity
Y-mAbs Therapeutics: A Yawn From The Market Means Opportunity #YmAbs #Therapeutics #Yawn #Market #Means #Opportunity
Keros Therapeutics: A Biotech Stock on the Move Amid Strategic Review and Rights Plan
In a move that’s got investors buzzing, Keros Therapeutics (NASDAQ: KROS) has announced a review of…
Sage Therapeutics: A Speculative Play That Needs To Wait For A Turnaround Story
Sage Therapeutics: A Speculative Play That Needs To Wait For A Turnaround Story #Sage #Therapeutics #Speculative…